U 78517F

iron-catalyzed lipid peroxidation inhibitor; structure given in first source; RN given is for diHCl

Also Known As:

2-((4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)methyl)-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol.di-HCl; 2-MAC; 2-methyl aminochroman; PNU 83836E; PNU-83836E; PNU83836E; U 78517F, (R)-isomer; U 78517F, (S)-isomer; U 78517F, citrate salt (1:2); U 78517G; U 83836E; U-78,517G; U-78517F; U-78517G; U-83836E; U78517F

Networked: 32 relevant articles (10 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromans: 3
        U 78517F: 32
  - Piperazines: 26
    - U 78517F: 32
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromans: 3
        U 78517F: 32

Experts

1.	Labruto, Fausto: 1 article (01/2006)
2.	Song, Xiaoliang: 1 article (01/2006)
3.	Vaage, Jarle: 1 article (01/2006)
4.	Valen, Guro: 1 article (01/2006)
5.	Erol, Kevser: 1 article (01/2004)
6.	Kabadere, Selda: 1 article (01/2004)
7.	Korkmaz, Seval: 1 article (01/2004)
8.	Oztopçu, Pinar: 1 article (01/2004)
9.	Uyar, Ruhi: 1 article (01/2004)
10.	Akyüz, Fahrettin: 1 article (05/2003)

Related Diseases

1.	Ischemia 11/01/1990 - "Nonsteroidal lazaroid U78517F in models of focal and global ischemia." 08/01/1991 - "U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia." 11/01/1990 - "In a separate series of experiments with the same focal ischemia model, identical dosing with U78517F enhanced the postischemic recovery of cortical extracellular calcium without any effect on ischemic or postischemic cortical blood flow. " 01/01/2006 - "The authors hypothesized that lazaroid U-83836E may be beneficial in a shock model with hemorrhage combined with limb ischemia. " 01/01/2006 - "Lazaroid U-83836E improves tolerance to hemorrhagic shock and limb ischemia and reperfusion in rats and increases cardiac heat shock protein 72."
2.	Shock 05/01/1998 - "Protective effects of the new lazaroid "U-83836E" in splanchnic artery occlusion (SAO) shock." 05/01/1998 - "We studied the effects of the new antioxidant drug U-83836E during splanchnic artery occlusion (SAO) shock in the rat. " 01/01/2006 - "The authors hypothesized that lazaroid U-83836E may be beneficial in a shock model with hemorrhage combined with limb ischemia. " 07/01/1998 - "Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a 'second generation' lazaroid in rats."
3.	Polydipsia 01/01/1995 - "After the first month of treatment U-83836E improved significantly the protective effect of vanadate alone on polydipsia and polyuria, but more efficiently on hyperglycemia and glycosuria. " 09/01/1994 - "At subsequent steps, U-83836E significantly improved the protective effect of vanadate alone on polydipsia and polyuria, but especially on hyperglycemia and glycosuria. "
4.	Polyuria 01/01/1995 - "After the first month of treatment U-83836E improved significantly the protective effect of vanadate alone on polydipsia and polyuria, but more efficiently on hyperglycemia and glycosuria. " 09/01/1994 - "At subsequent steps, U-83836E significantly improved the protective effect of vanadate alone on polydipsia and polyuria, but especially on hyperglycemia and glycosuria. "
5.	Hyperglycemia 01/01/1995 - "After the first month of treatment U-83836E improved significantly the protective effect of vanadate alone on polydipsia and polyuria, but more efficiently on hyperglycemia and glycosuria. " 09/01/1994 - "At subsequent steps, U-83836E significantly improved the protective effect of vanadate alone on polydipsia and polyuria, but especially on hyperglycemia and glycosuria. "

Related Drugs and Biologics

1.	Superoxide Dismutase
2.	Vanadates (Orthovanadate)
3.	Free Radicals
4.	Catalase
5.	Antioxidants
6.	U 74389F
7.	tirilazad
8.	Deferoxamine (Desferal)
9.	Vitamin E
10.	Ovalbumin

Related Therapies and Procedures

1.	Intravenous Administration
2.	Resuscitation
3.	Intravenous Injections
4.	Intraperitoneal Injections
5.	Oral Administration